Reference: I-PREVENT. (2023). COVID, Flu and RSV protection. Retrieved from [source link if applicable, otherwise remove this line] Summary: The I-PREVENT protocol offers strategies for the prevention of COVID-19, influenza, and RSV. It includes pre-exposure and post-exposure prevention measures, particularly aimed at high-risk groups and healthcare workers. The pre-exposure approach recommends the use of antiseptic […]
Reference: Pfizer. (2023). NCT04368728 FDA Clinical Trial: C4591001. Retrieved from [link to the document] Summary: The clinical trial NCT04368728, with protocol number C4591001, aims to evaluate the safety, tolerability, immunogenicity, and efficacy of RNA vaccine candidates against COVID-19 in healthy individuals. The trial is structured in three phases, assessing different doses and age groups, with
Reference: Boschi, C., Scheim, D. E., Bancod, A., Millitello, M., Le Bideau, M., Colson, P., Fantini, J., & La Scola, B. (2022). SARS-CoV-2 spike protein induces hemagglutination: Implications for COVID-19 morbidities and therapeutics and for vaccine adverse effects. bioRxiv. https://doi.org/10.1101/2022.11.24.517882 Summary: The study investigates the hemagglutination (HA) induced by SARS-CoV-2 spike proteins from various lineages
Reference: Demasi, M. (2022). FDA oversight of clinical trials is “grossly inadequate,” say experts. BMJ, 379, o2628. http://doi.org/10.1136/bmj.o2628 Summary: Experts are raising alarms about the US Food and Drug Administration’s (FDA) oversight of clinical trials, particularly following the expedited development of Covid-19 vaccines. A complaint by Brook Jackson, a former employee at Ventavia Research Group,
Reference: Anderson, S. (2020). CBER plans for monitoring COVID-19 vaccine safety and effectiveness. Vaccine and Related Biological Products Advisory Committee Meeting Presentation, October 22. FDA. Summary: The FDA’s Vaccines and Related Biological Products Advisory Committee meeting on October 22, 2020, provided insights into the agency’s plans for monitoring the safety and effectiveness of COVID-19 vaccines.
Reference: Bramante, C. T., Huling, J. D., Tignanelli, C. J., Buse, J. B., Liebovitz, D. M., Nicklas, J. M., Cohen, K., Puskarich, M. A., Belani, H. K., Proper, J. L., Siegel, L. K., Klatt, N. R., Odde, D. J., Luke, D. G., Anderson, B., Karger, A. B., Ingraham, N. E., Hartman, K. M., Rao, V.,
Reference: Marik, P. E., Kory, P., & Contributors. (2022). I-RECOVER: Post-Vaccine Treatment protocol (5/25/2022). An Approach to the Management of Post-Vaccine Syndrome. Summary: The I-RECOVER protocol is designed to aid healthcare professionals in managing patients with post-vaccine syndrome, a condition arising from COVID-19 vaccinations. While no formal definition exists, symptoms correlating temporally with vaccination can
Reference: Kory, P., Marik, P., et al. (2022). I-RECOVER: Post-Vaccine Treatment protocol. Summary: The I-RECOVER protocol offers guidance for healthcare professionals treating patients experiencing post-vaccine syndrome, a condition with symptoms emerging or worsening following COVID-19 vaccination. Contributors, including prominent physicians, acknowledge the lack of formal recognition and classification for this syndrome by major health organisations,
Reference: Marik, P. (2022. COVID-19 management protocol. FLCCC Alliance. Retrieved from www.flccc.net Summary: The FLCCC Alliance’s COVID-19 Management Protocol, developed by Dr Paul Marik, outlines strategies for managing COVID-19 through three primary protocols: MATH+, I-MASK+, and I-RECOVER. The MATH+ protocol focuses on treating patients in the pulmonary phase, utilising anti-inflammatory therapies and corticosteroids to reduce